How long can you live with pT3a prostate cancer?

The 10-year carcinoma-specific survival rates were: 98% for patients with stage pT3a (N = 2675; 10-year biochemically recurrence-free survival 53%; 10-year overall survival 89%) 87% for patients with stage pT3b (N = 1373; 10-year biochemically recurrence-free survival 18%; 10-year overall survival 79%)

Table of Contents

Can prostate cancer recurrence be cured?

A prostate cancer recurrence is often treatable. It may even be curable. The treatments you’ll get this time around will be different from the ones you had before. Finding out your cancer has returned can bring back some of the same emotions you felt after your initial diagnosis.

Is Pi-RADS 5 treatable?

In this case, based on our experience, the presence of a very high suspicion, PI-RADS 5, abnormality could have allowed for treatment without repeat biopsy, based on the very high rate of treatment following repeat biopsy (Figure 3).

Is pT3a curable?

Our single center study shows that surgical treatment may indeed be a reasonable treatment option in locally advanced pT3a PCa with 96% OS, 98.7% CSS, 97.3% DPFS and 60% BPFS at the 5-year follow-up mark. The survival rates of the pT3a patients in our study are similar to those reported by Hsu et al.

Is recurrent prostate cancer more aggressive?

If you did not have a prostatectomy before, your doctor will likely recommend one now. This is important as recurrent prostate cancer is more aggressive and can result in the cancer spreading to lymph nodes and bone if not addressed quickly.

Why can’t you have your prostate removed after radiation?

After radiation therapy: If your first treatment was radiation, treatment options might include cryotherapy or radical prostatectomy, but when these treatments are done after radiation, they carry a higher risk for side effects such as incontinence.

What is the success rate of radiation therapy for prostate cancer?

Men with localised prostate cancer who are treated with external-beam radiation therapy have a cure rate of 95.5% for intermediate-risk prostate cancer and 91.3% for high-risk prostate cancer. The 5-year survival rate using this treatment is 98.8% overall.